MPM kicks off a new I/O player with $44.5M round and a new understanding of the T cell receptor

After running in stealth mode for more than a year gaining better understanding of the complex structure of subunits involved in the T cell receptor, TCR² has now jumped into view in Cambridge, MA with a $44.5 million startup round and some big plans to make some original progress in immuno-oncology.

Garry Menzel, the former COO at Regulus, has taken charge as the new CEO. He’s teaming up with ex-Merck KGaA scientist Robert Hofmeister, who’s credited with a senior role in developing that company’s PD-L1 checkpoint, and Patrick Baeuerle, the former CSO at Micromet.

The big idea here is that they can start to leverage their understanding of the T cell receptor structure to make a better cell therapy to fight cancer, breaking down barriers that have limited efficacy as well as extending their range into solid tumors.

“The T cell receptor with its six distinct subunits is arguably the most complex receptor found in the human body. Growing evidence suggests that all TCR subunits interact with each other in a unique and critical way to determine the strength, duration and quality of response inside T cells. Because the TCR2 TRuC variants are designed to become an integral part of the TCR complex, TRuC-engineered T cells can take advantage of the full signal transduction power of the TCR complex, which is likely needed to improve efficacy of T cell therapies in solid tumors,” said Dr. Baeuerle.

MPM Capital provided the seed funding needed to get the company started in 2015, and Baeurle is credited as a co-founder. MPM and F2 Ventures provided the A round together.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,100+ biopharma pros who read Endpoints News by email every day.

Free Subscription

VP Oncology Biology
Skyhawk Therapeutics Waltham, MA
Director Process Development
Elektroki Boston, MA
Director Process Development
Elektroki Boston, MA
Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT

Visit Endpoints Careers ->